Guttmacher Institute’s Post

Louisiana lawmakers have voted to pass legislation to classify mifepristone and misoprostol, two FDA-approved drugs used for medication abortion, as schedule IV drugs. This first-in-the-nation legislation is unconscionable and dangerous, and more than 200 doctors in LA have come forward to state that it will "delay access to care and worsen outcomes." This legislation will build on the current near-total abortion ban and will have resounding harmful impacts on patients, their families, and health care providers. #bansoff https://lnkd.in/eTzmRM5d

Today, the U.S. Supreme Court hears the FDA challenge of a lower court ruling that it must reinstate the guidelines placed on the chemical abortion drug mifepristone when it was first approved in 2000. Since then, the FDA has rolled back several of these safeguards, such as the requirement for in-person dispensation of mifepristone by the prescriber, which has opened the door for dangerous mail-order abortions with no medical supervision. This case is crucial for the safety of our patients. -The American Association of Pro-Life Ob/Gyns (AAPLOG) #aaplog #allianceforhippocraticmedicine #aaplogfdalawsuit #aaplogchemicalabortion #aaplogscientificscholarship #aaplogmedicalevidence #joinaaplogtoday

The latest from 340B Report: Missouri GOP Lawmaker Slams State AG’s ‘Irresponsible’ Claims Linking 340B Bill to Abortion As Governor’s Decision Looms -https://lnkd.in/e76zdh6y Supreme Court ‘Chevron’ Ruling Increases Pressure on Congress to Act on 340B But Unlikely to Immediately Impact Program Oversight - https://lnkd.in/eHTDEznW Patient Turned Advocate: David Alexander Discusses 340B - https://lnkd.in/eeiV4ixq Viatris Becomes 37th Manufacturer to Place Restrictions on 340B Contract Pharmacy Use; Policy Applies to Hospitals and Health Centers - https://lnkd.in/e_9CUGpk More Drugmakers Exempt States from Contract Pharmacy Restrictions as Four New State Laws Take Effect - https://lnkd.in/eqDtqGyM Delaware Legislature Passes Anti-Discrimination Protections for 340B Providers from PBMs but Drug Manufacturer Restrictions Remain - https://lnkd.in/ePr88ZWd Hospital Groups Urge Federal Court to Uphold Maryland’s 340B Contract Pharmacy Access Law - https://lnkd.in/eGTVa5Mw Hospitals in Texas and Other States Sue HHS Over DSH Calculation Changes That Impact 340B Eligibility - https://lnkd.in/eu6mueK8 Verity Panel Discussion: 340B Outlook from Washington, D.C. & the States - https://lnkd.in/e6MxBgJv To get full access to 340B Report news reporting and analysis, visit https://lnkd.in/gJd7qNyg #340B #pharmacy #drugpricing #hospitals #hospitalpharmacy

Louisiana's governor on May 24 signed a bill making his state the first in the U.S. to classify two abortion-inducing medications as controlled substances, a category that healthcare regulators typically reserve for drugs prone to abuse or addiction. The new law designates mifepristone and misoprostol, which the FDA approved more than two decades ago as safe and effective for terminating pregnancies, as Schedule IV drugs, typically pain-killers and mood-altering medications that merit greater oversight due to their potential for abuse or dependence. The measure, thrusting Republican-led efforts to restrict abortion back to the political forefront in a presidential election year, was signed into law by Republican Governor Jeff Landry a day after the state legislature sent it to his desk. The bill cleared Louisiana's Republican-majority House of Representatives and Senate by wide margins, even as efforts by the U.S. Food and Drug Administration to expand access to abortion pills is facing a legal challenge before the Supreme Court. Find out more: https://reut.rs/4bw0w1t 

The Supreme Court's decision in Food and Drug Administration v. Alliance for Hippocratic Medicine upholds continued access to mifepristone, backed by over 20 years of scientific evidence. The Court found that the Alliance lacked standing to challenge the FDA's regulation, a case that should not have reached this level. Rooted in historical issues of white supremacy and the the desire to control people’s reproductive autonomy and decision making, the Alliance's argument reflects deeper societal challenges. Legal scholars highlight the significance of the in-person pick-up restriction on mifepristone, removed during the COVID pandemic to ensure access. This change is seen as pivotal in making medication abortion more difficult to control. We have seen a huge politicization of science. Over decades the anti-abortion movement has fueled an obvious cultural shift by challenging science and defending ideologically skewed and often false information about abortion. Today is a win for medication abortion access. However, the target remains because access to abortion has radically changed. Allowing people to get access to abortion even when their state banned abortion in its borders through telehealth and pharmacy mailing liberates abortion in a way that will not be easily reversed. #AbortionAdvocacy #AbortionRights #Mifepristone

BREAKING: #SCOTUS issued a unanimous decision in the FDA v. Alliance for Hippocratic Medicine case, affirming the safety, effectiveness, and essential role of mifepristone in nationwide healthcare access. This decision ensures that mifepristone, a safe and effective medication, remains widely available for those who need it. However, the fight for reproductive freedom is far from over. We must remain vigilant and continue our efforts to safeguard abortion access. We need you to vote this November to ensure that reproductive healthcare remains accessible once and for all. #mifepristone #abortionpills #abortionmedication #reproductivehealth #reproductivejustice #abortionisessential

Free Speech Or Bad Medicine? The Abortion 'Reversal' Battle - Law360 Free Speech Or Bad Medicine? The Abortion 'Reversal' Battle  Law360 Learn more https://lnkd.in/eTT3M2f7

Today, after extensive briefing and oral argument in April, the U.S. Supreme Court declined to review 𝑀𝑜𝑦𝑙𝑒 𝑣. 𝑈𝑛𝑖𝑡𝑒𝑑 𝑆𝑡𝑎𝑡𝑒𝑠, which posed whether federal law requires hospital emergency rooms, in delivering emergency healthcare, must also offer emergency abortion access to pregnant patients in appropriate circumstances, regardless of state law: https://lnkd.in/eYH8J6bt   The decision today leaves that question open, and the lower court's order permitting emergency abortions in Idaho remains intact for now while litigation continues. Our view, however, hasn't changed. In an emergency room, any patient would naturally expect prompt, stabilizing medical care. Federal law requires no less, and it is no different for pregnant patients in emergencies where the stakes are high. In an amicus brief to SCOTUS with nearly 100 organizations, NAPABA argued what we believe federal law makes plain: pregnant patients are entitled to meaningful access to emergency healthcare, including emergency abortion access. Read our brief here: https://t.co/JAQ28AxzRj

Iowa's fetal heartbeat law, House File 732, took effect on July 29. It bans abortions after a fetal heartbeat is detected, with exceptions for rape, incest, non-viability of the fetus, and medical emergencies. Understanding this law and its implications is crucial for hospitals and providers in Iowa. Explore the law and its impact on healthcare practices here: https://lnkd.in/gdPZqtzz Alissa Smith | Lillie C. Cox

Restrictive abortion laws are more than policies; they’re shackles on our healthcare providers. These laws prevent doctors from offering the essential care they are trained and sworn to provide. It’s time to unlock the potential of medical care free from unnecessary restrictions. 👉 Stand with us in defending the freedom to care. Every patient deserves access to comprehensive healthcare, and every doctor deserves the right to provide it. https://lnkd.in/g4nk3rek